{"doi":"10.1016/j.cjca.2025.06.003","title":"Frailty Risk After a Cardiovascular Event Among Community-Dwelling Older People: Influence of Sociodemographic, Polypharmacy, and Pre-event Frailty","abstract":"BACKGROUND: Frailty is a significant concern for older adults and can increase after a major health event. This study examined the risk of incident frailty after a cardiovascular disease (CVD) event among community-dwelling older people aged ≥ 65 years and explored whether sociodemographic factors, polypharmacy, and pre-event frailty influence their risk of developing frailty after a CVD event. METHODS: This study included a cohort of 738 participants (38.5% women) from the ASPREE study who were not classified as frail before their CVD event. Frailty was measured annually using the 64-item deficit-accumulation frailty index. RESULTS: Over an average 2.6 years after a CVD event, 333 individuals had incident frailty. In logistic regression models, increased chronological age, being a woman, and having polypharmacy were associated with 4% to 83% increased odds of developing frailty after a CVD event. Individuals with CVD residing in the inner regional area had about 50% higher odds of having frailty than those living in cities. This association was more evident among stroke survivors, with both inner regional (adjusted odds ratio [OR] 2.13) and outer regional or remote residents (adjusted OR 2.37) having greater odds of frailty. Individuals who were classified as pre-frail before their CVD event, had notably higher odds of progressing to frailty after the CVD event (adjusted OR 3.41). CONCLUSIONS: Our community-based study provides robust evidence that individuals who were women, older, pre-frail, with polypharmacy, and living in regional or remote areas have a markedly greater odds of developing frailty after a CVD event.","journal":"Canadian Journal of Cardiology","year":2025,"id":567914,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9645,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":284811,"name":"Andrew Tonkin","orcid":"0000-0001-5291-0610","position":1,"is_corresponding":false},{"id":404570,"name":"Sara Espinoza","orcid":"0000-0002-1116-302X","position":2,"is_corresponding":false},{"id":661565,"name":"ARM Saifuddin Ekram","orcid":"0000-0003-4267-1286","position":3,"is_corresponding":false},{"id":264292,"name":"Robyn L. Woods","orcid":"0000-0003-1249-6149","position":4,"is_corresponding":false},{"id":332013,"name":"Joanne Ryan","orcid":"0000-0002-7039-6325","position":5,"is_corresponding":false},{"id":686179,"name":"Aung Zaw Zaw Phyo","orcid":"0000-0002-8834-4072","position":0,"is_corresponding":true}],"reference_count":47,"raw_metadata":null,"created_at":"2026-07-19T02:56:48.183032Z","pmid":"40513825","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}